Want to join the conversation?
$AMAT 3Q15 Q&A: Sankar, BofA: Should we assume GM will be under pressure if Jan. revenues come up? Bob replied, a company like AMAT, our product cost is materials, stuff we buy, so you don’t get this big absorption boost or downtick either with volume. So our GM is predominantly a function of mix between customers, mix between products.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.